证券代码：688217 证券简称：睿昂基因 公告编号：2025-037 上海睿昂基因科技股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任 重要内容提示： 分配比例：每 10 股派发现金红利 1.70 元（含税），不进行公积金转增 股本，不送红股。 本次利润分配拟以上海睿昂基因科技股份有限公司（以下简称"公司"） 2025 年半年度实施权益分派股权登记日登记的总股本扣减公司回购专用证券账 户中的股份为基数分配利润，具体日期将在权益分派实施公告中明确。 如在本公告披露之日起至实施权益分派股权登记日期间，公司总股本扣 减公司回购专用证券账户中的股份数量发生变动的，公司拟维持每股分配比例不 变，相应调整分配总额。如后续总股本发生变化，将另行公告具体调整情况。 本次利润分配方案尚需提交公司 2025 年第二次临时股东大会审议。 一、利润分配方案内容 截至 2025 年 6 月 30 日，公司合并报表中未分配利润为人民币 140,339,334.45 元，母公司报表中未分配利润余额 ...

上海睿昂基因科技股份有限公司2025 年半年度报告 重要提示 上海睿昂基因科技股份有限公司 2025 年半年度报告 1 / 249 上海睿昂基因科技股份有限公司2025 年半年度报告 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真 实性、准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 二、 重大风险提示 公司已在本报告中描述可能存在的风险，敬请查阅"第三节管理层讨论与分析" 之"四、风险因素"部分，请投资者注意投资风险。 公司代码：688217 公司简称：睿昂基因 三、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事长 | 熊慧 | 因被批捕无法亲自出席 | 高尚先 | 四、 本半年度报告未经审计。 五、 公司负责人高尚先、主管会计工作负责人王春娟及会计机构负责人（会计主管 人员）王春娟声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司 2025 年半年度利润 ...

Group 1 - The core viewpoint of the news highlights the significant increase in the stock price of Ruian Gene, which rose by 9.95% on August 26, with a trading volume of 148 million yuan [1] - On August 26, Ruian Gene had a financing purchase amount of 20.89 million yuan and a net financing purchase of 2.7854 million yuan, indicating strong investor interest [1] - As of August 26, the total balance of margin trading for Ruian Gene was 71.03 million yuan, accounting for 3.70% of its market capitalization, which is above the 80th percentile of the past year [1] Group 2 - Ruian Gene, established on February 17, 2012, specializes in the research, production, and sales of in vitro diagnostic products, primarily focusing on precision testing for blood diseases, solid tumors, and infectious diseases [2] - The company's revenue composition includes 84.71% from self-produced reagents, 8.52% from testing services, and 1.90% from research services, indicating a strong reliance on its own products [2] - For the first quarter of 2025, Ruian Gene reported a revenue of 54.738 million yuan, a year-on-year decrease of 14.72%, while its net profit attributable to the parent company was 3.355 million yuan, showing a significant increase of 529.26% [2] Group 3 - Since its A-share listing, Ruian Gene has distributed a total of 10.0541 million yuan in dividends [3] - As of March 31, 2025, the number of shareholders for Ruian Gene was 3,990, a decrease of 6.54% from the previous period, while the average circulating shares per person increased by 6.99% [2][3] - Among the top ten circulating shareholders, Huaxia CSI 500 Index Enhanced A (007994) is a new entrant, holding 531,500 shares [3]

Core Insights - The report highlights the significant compensation of CFOs in the A-share market, with a total salary scale of 4.27 billion yuan and an average annual salary of 814,800 yuan for 2024 [1] - The pharmaceutical and biotechnology sector shows a higher average CFO salary of 919,700 yuan, which is 12.8% above the overall market average [1] - In Shanghai, the average CFO salary in the pharmaceutical sector reaches approximately 1,139,100 yuan, 39.8% higher than the market average, reflecting the high operational costs and talent competition in the region [1] CFO Salary Rankings - The top ten CFOs in Shanghai's pharmaceutical sector include notable figures such as Shen Bo from Shanghai Medical with a salary of 3.054 million yuan and a growth rate of 5.75% [2] - Li Yan from Ruian Gene ranks seventh with a salary of 1.573 million yuan, marking a 15.49% increase from the previous year [2][3] Company Performance - Ruian Gene reported a total revenue of 242 million yuan for 2024, a decline of 6.16% year-on-year, and a net profit of -16 million yuan, indicating a significant downturn [4] - The company's stock price fell by 48.46%, with a market capitalization of 1.03 billion yuan by the end of 2024, alongside facing compliance penalties [5] Talent Competition - The report emphasizes the strategic importance of top-tier financial executives in high-value industries, driven by the dual factors of core regional advantages and high-value industry characteristics [5]

Market Overview - On August 1, the medical device sector rose by 0.18% compared to the previous trading day, with Lidman leading the gains [1] - The Shanghai Composite Index closed at 3559.95, down 0.37%, while the Shenzhen Component Index closed at 10991.32, down 0.17% [1] Top Gainers in Medical Device Sector - Lidman (300289) closed at 8.45, up 20.03% with a trading volume of 588,100 shares and a transaction value of 496 million yuan [1] - Rejing Bio (688068) closed at 216.50, up 11.03% with a trading volume of 44,000 shares and a transaction value of 948 million yuan [1] - Guanwu Bio (300238) closed at 19.00, up 9.20% with a trading volume of 470,900 shares and a transaction value of 878 million yuan [1] - Yingke Medical (300677) closed at 37.28, up 8.53% with a trading volume of 447,500 shares and a transaction value of 1.643 billion yuan [1] - Other notable gainers include Zhonghong Medical (300981), Sainuo Medical (688108), and Kemei Diagnosis (688468) with respective increases of 8.05%, 6.70%, and 6.66% [1] Top Losers in Medical Device Sector - Huakang Clean (301235) closed at 33.10, down 5.97% with a trading volume of 158,600 shares [2] - Kangtai Medical (300869) closed at 19.80, down 4.35% with a trading volume of 284,800 shares and a transaction value of 571 million yuan [2] - Other significant decliners include XD Chunli Medical (688236), Haooubo (688656), and Huqiang Technology (688151) with respective declines of 3.67%, 3.13%, and 3.10% [2] Capital Flow in Medical Device Sector - On the same day, the medical device sector saw a net inflow of 40.108 million yuan from institutional investors, while retail investors experienced a net outflow of 93.3185 million yuan [2][3] - Notable net inflows from institutional investors included Lepu Medical (300003) with 57.2395 million yuan and Guanwu Bio (300238) with 57.033 million yuan [3] - Conversely, significant net outflows from retail investors were observed in Lepu Medical (-82.3375 million yuan) and Guanwu Bio (-11.5 million yuan) [3]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：688217 证券简称：睿昂基因 公告编号：2025-034 上海睿昂基因科技股份有限公司(以下简称"公司")全资子公司上海源奇生 物医药科技有限公司于近日收到政府补助资金共人民币 176.29 万元，为与收益 相关的政府补助。 二、补助的类型及其对上市公司的影响 根据《企业会计准则第 16 号—政府补助》的相关规定，公司上述获得的政 府补助属于与收益相关的政府补助。上述政府补助未经审计，具体的会计处理 以及对公司损益的影响最终以审计机构年度审计确认后的结果为准。敬请投资 者注意投资风险。 特此公告。 上海睿昂基因科技股份有限公司董事会 2025 年 7 月 2 日 上海睿昂基因科技股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获取补助的基本情况 ...

关于对上海睿昂基因科技股份有限公司 2024 年度审计报告出具带强调事项段无保留意见 的专项说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 关于对上海睿昂基因科技股份有限公司 2024年度审计报告出具带强调事项段无保留意见 的专项说明 中汇会专[2025]4209号 上海证券交易所: 我们接受委托,依据中国注册会计师审计准则审计了上海睿昂基因科技股份 有限公司(以下简称睿昂基因公司)2024年12月31日的合并及母公司资产负债表, 2024年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有 者权益变动表以及财务报表附注,并于2025年4月16日出具了中汇会审[2025]4206 号带强调事项段无保留意见的审计报告。 表整体的重要性水平为183.77万元。睿昂基因公司近年来经 ...

Core Viewpoint - The legal opinion letter confirms that the 2024 annual general meeting of Shanghai Ruiang Gene Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [2][14]. Group 1: Meeting Procedures - The annual general meeting was convened by the company's board of directors, with the notice published 20 days prior to the meeting date [4][5]. - The meeting utilized a combination of on-site and online voting methods, with specific time slots designated for each voting method [5][14]. Group 2: Attendance and Voting - A total of 33 shareholders and their proxies attended the meeting, representing 17,949,661 shares, which is 32.5256% of the total voting shares [6]. - The meeting included 3 shareholders present on-site, representing 10,804,197 shares (19.5777% of total voting shares), while 30 shareholders participated via online voting [6][7]. Group 3: Resolutions Passed - The meeting approved several resolutions, including: - The 2024 Board of Directors' Work Report, with 99.3652% approval from attending shareholders [8]. - The 2024 Supervisory Board's Work Report, also receiving 99.3652% approval [9]. - The 2024 Financial Settlement Report, with the same level of approval [10]. - The 2025 Financial Budget Report, approved by 99.3391% of attending shareholders [10]. - The 2024 Profit Distribution Plan, receiving 99.3652% approval [10]. - The 2024 Annual Report and its summary, with 99.3652% approval [11]. - The 2025 Director Remuneration Plan, approved by 99.2735% of attending shareholders [12]. - The 2025 Supervisor Remuneration Plan, also receiving 99.2735% approval [12]. - The proposal for a comprehensive credit limit application to banks for 2025, approved by 99.2980% of attending shareholders [13]. Group 4: Legal Compliance - The legal opinion confirms that the meeting's convening, attendance, voting procedures, and resolutions comply with the Company Law, Securities Law, and other relevant regulations [14].

证券代码：688217 证券简称：睿昂基因 公告编号：2025-033 上海睿昂基因科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 20 日 （二） 股东大会召开的地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 33 | | --- | --- | | 普通股股东人数 | 33 | | 2、出席会议的股东所持有的表决权数量 | 17,949,661 | | 普通股股东所持有表决权数量 | 17,949,661 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 32.5256 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 32.5256 | ...